Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets.
The company has invested heavily in research and development and marketing for two drugs in particular, donanemab for treatment of Alzheimer's disease and tirzepatide for obesity. They are planning on releasing data from testing phases soon and gaining approval for donanemab early in 2023.
The company’s shares have been up this past year, by 31%, although they have predicted a lower profit margin in 2023 due to higher spending and share prices falling by 1%.
Tirzepatide, under the brand name Mounjaro, gained approval from the US regulators in 2022 for use in treating type 2 diabetes to be administered as a once-weekly subcutaneous injection.
Eli Lilly are anticipating costs associated with the drug’s marketing and other expenses to hit in the region of $6.9 billion to $7.1 billion, $500 million more than in 2022.
"I think we see two of them as kind of generational opportunities, tirzepatide for obesity and donanemab, and the other three as being great opportunities in very competitive spaces," Lilly Chief Executive David Ricks stated.
The other drugs in the portfolio to be released next year are mirikizumab for inflammatory bowel disease, lebrikizumab for atopic dermatitis, and pirtobrutinib for the treatment of multiple B-cell malignancies.
Lilly is also projecting a spend of $8.2 billion to $8.4 billion on their research and development programmes.
Refinitiv, the financial market data and infrastructure provider, is predicting that these large-scale investments will pay off, projecting revenue of between $30.3 billion and $30.8 billion in 2023 for Eli Lilly.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance